Colony Stimulating Factor 2, Granulocyte Macrophage (GMCSF)
In a new study, researchers from the Mayo clinic in the United States have developed a strategy that could improve the performance of chimeric antigen receptor (CAR) t-cell (car-t cell) therapies in treating cancer. Relevant research results are recently published in the journal Blood. The paper is entitled "gm-csf inhibiting, reducing cytokine release syndrome and neuroinflammation but enhances car-t cell function in xenografts". Corresponding author Saad Kenderian, a hematologist at Mayo clinic. "Although car-t cell therapy has been successful in some cancers, its widespread use has been limited by its severe toxicity," Sterner said. Toxicity associated with car-t cell therapy includes cytokine release syndrome, in which patients experience symptoms such as fever, nausea, headache, rash, increased heart rate, hypotension, difficulty breathing, and neurotoxicity.
Sterner says some patients who receive car-t cell therapy get sick during treatment and need to stay in intensive care units (ICU) for a while. She also noted that deaths associated with side effects of car-t cell therapy have been reported. Sterner and her colleagues developed a strategy to reduce the toxic side effects associated with car-t cell therapy. This strategy involves blocking the release of granulocyte macrophage colony stimulating factor (gm-csf) by car-t cells and other cells using lenzilumab, a clinical-level antibody.
"When we blocked the gm-csf protein, we found that we were able to reduce toxicity in a preclinical model," Sterner said. We are also able to demonstrate that car-t cells function better after gm-csf protein is blocked. Next, the researchers used CRISPR/Cas9 gene editing to produce car-t cells that do not secrete gm-csf proteins. Sterner says these genetically modified CAR T cells function more efficiently than normal CAR T cells.
Based on these findings, the researchers are conducting phase II clinical trials using gm-csf blocking antibodies during car-t cell therapy. If the results of this clinical trial are consistent with earlier findings, the treatment could become standard at Mayo during car-t cell therapy.
At present, DLDEVELOP co. LTD has developed corresponding GMCSF Elisa products. To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-gmcsf-c.html
https://dldevelop.com/Research-reagent/dl-gmcsf-hu.html
https://dldevelop.com/Research-reagent/dl-gmcsf-mu.html
https://dldevelop.com/Research-reagent/dl-gmcsf-ra.html
Sterner says some patients who receive car-t cell therapy get sick during treatment and need to stay in intensive care units (ICU) for a while. She also noted that deaths associated with side effects of car-t cell therapy have been reported. Sterner and her colleagues developed a strategy to reduce the toxic side effects associated with car-t cell therapy. This strategy involves blocking the release of granulocyte macrophage colony stimulating factor (gm-csf) by car-t cells and other cells using lenzilumab, a clinical-level antibody.
"When we blocked the gm-csf protein, we found that we were able to reduce toxicity in a preclinical model," Sterner said. We are also able to demonstrate that car-t cells function better after gm-csf protein is blocked. Next, the researchers used CRISPR/Cas9 gene editing to produce car-t cells that do not secrete gm-csf proteins. Sterner says these genetically modified CAR T cells function more efficiently than normal CAR T cells.
Based on these findings, the researchers are conducting phase II clinical trials using gm-csf blocking antibodies during car-t cell therapy. If the results of this clinical trial are consistent with earlier findings, the treatment could become standard at Mayo during car-t cell therapy.
At present, DLDEVELOP co. LTD has developed corresponding GMCSF Elisa products. To get more information, you could contact our professional staff directly or directly to our website:
https://dldevelop.com/Research-reagent/dl-gmcsf-c.html
https://dldevelop.com/Research-reagent/dl-gmcsf-hu.html
https://dldevelop.com/Research-reagent/dl-gmcsf-mu.html
https://dldevelop.com/Research-reagent/dl-gmcsf-ra.html
